News – Ping An-Shionogi

2022.12.29

Press Release

Ping An-Shionogi Signs an Agreement with Chia Tai Tianqing Pharmaceutical, a subsidiary of Sino Biopharmaceutical, for Domestic Promotion of Ensitrelvir, a Therapeutic Drug for COVID-19
2022.12.23

Press Release

Ping An-Shionogi Signs a License Agreement for Import and Domestic Distribution of Ensitrelvir, a Therapeutic Drug for COVID-19
2022.11.23

Notice

Shionogi Announces Xocova® (Ensitrelvir Fumaric Acid) Tablets 125mg Approved in Japan for the Treatment of SARS-CoV-2 Infection, under the Emergency Regulatory Approval System
2022.09.29

Notice

Shionogi Announces Achievement of the Primary Endpoint for Ensitrelvir Fumaric Acid (S-217622) in the Phase 3 part of the Phase 2/3 Clinical Trial in Asia
2022.07.04

Notice

Ping An-Shionogi Initiates the Submission of the Preparation Materials for New Drug Application for S-217622, a Therapeutic Drug for COVID-19, in China
2021.06.30

Press Release

Ping An-Shionogi Initiated a New Collaboration with Ping An-Health for Real World Data (RWD) Collection and Analysis Research